MedPath

Personalized Management of Psycho-behavioral Symptoms in Alzheimer's Disease: Impact on Health Resources Use

Not Applicable
Recruiting
Conditions
Alzheimer's Disease
Interventions
Behavioral: personalized care preceded by a standardized assessment
Registration Number
NCT04820127
Lead Sponsor
University Hospital, Toulouse
Brief Summary

The present project propose to study the effectiveness of a personalized care management of psycho-behavioral symptoms based on an evidence-based standardized assessment to identify and understand the underlying causes of psycho-behavioral symptoms followed by a personalized intervention based on targeted and prioritized actions. This personalized intervention is proposed both to Alzheimer disease (AD) patients living at home with agitation-type psycho-behavioral symptoms, and also to their caregivers with the support and coordination of a nurse working in collaboration with the specialist physician and the General Practitioner (GP). News technologies are used to enhance the follow-up, based on telehealth, and caregiver training.

The project hypothesize that, for a vulnerable population at risk (AD patient with agitation and their caregivers) living at home, a personalized intervention, carried out and coordinated by a nurse in close collaboration with the specialist and GP, would reduce hospitalizations and have a positive effect on the disease evolution and caregiver distress. Also this personalized intervention could reduce the cost of care, in particular by reducing the costs associated with hospitalizations and informal help.

Detailed Description

PERSON-AL is a multicentric, interventional, open-label, randomized, parallel-group, stratified by centre, study comparing two arms: usual care versus intervention (personalized care preceded by a standardized assessment)

Principal Objective : To evaluate the impact of a personalized intervention for the management of agitation due to psycho-behavioral symptoms on the use of scheduled and unscheduled hospitalizations at 18 months in patients with AD and related disorders.

Secondary Objectives:

A- To evaluate the impact of a personalized intervention at 18 months on:

For the patient:

1. Unscheduled hospitalizations,

2. Severity of agitation symptoms,

3. The frequency and severity of emerging psycho-behavioral symptoms, other than agitation,

4. Prescription of psychotropic drugs,

5. Quality of life.

For the caregiver:

6. Distress related to psycho-behavioral symptoms,

7. All causes hospitalizations,

8. Quality of life.

B- Evaluate the medico-economic impact of this personalized intervention, and in particular:

1. Its efficiency compared to usual management by means of cost-effectiveness and cost-utility analyses, from the community perspective and over a time horizon of 18 months,

2. The actual cost of patient's standardized assessment and personalized management

3. The use of care and associated costs for the caregiver and the efficiency of caregiver targeted intervention.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
668
Inclusion Criteria

For the patient :

  • Diagnosed with major neuro-cognitive disorders (DSM V) at all severity stages.
  • Leaving at home
  • Assisted by a caregiver, from patient's family or personal environment, assuming most of patient care (spending at least 6 hours per week with the patient)
  • caregiver available to come with the patient to study visits as planned per protocol
  • existing agitation since at least one month (according to International Psychogeriatric Association (IPA) criteria)
  • agitation severity β‰₯ 2 , based on Clinician Global Impression of Severity (CGI-S) (at least mild severity)
  • the patient, his/her family member/trusted person , or his /her legal responsible has provided written informed consent to participate in the study
  • referring physician's oral approval obtained for patient participation in the study
  • Affiliated to French Healthcare System

For the caregiver:

  • Has provided his/her written informed consent to participate in the study
  • Ability to understand and speak French properly, ability to complete the questionnaires and assess the patient.
  • Affiliated to French Healthcare System
Exclusion Criteria

For the patient:

  • Agitation symptoms attributable either to other concomitant prescriptions, or to other psychiatric or evolving somatic diseases.
  • Patient living in a residential care facility or having an institutionalization project within 6 months
  • Patient with clinically significant or unstable disease that could affect he/her ability to come for the study visit or complete the evaluations planned as per protocol
  • Concomitant participation to any other interventional research study
  • Patient under legal protection.

For the caregiver:

  • Caregiver under legal protection.
  • Limited internet access or caregiver feeling unable to use it

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intervention (personalized care program)personalized care preceded by a standardized assessmentPatients in the intervention group will benefit from personalized care preceded by a standardized assessment
Primary Outcome Measures
NameTimeMethod
patient's number of hospitalization at 18 monthsFrom the inclusion until End of Study, 18 months

number of all causes hospitalization, either scheduled or unscheduled, including emergency department visits

Secondary Outcome Measures
NameTimeMethod
patient's unscheduled hospitalizationFrom the inclusion until End of Study, 18 months

all causes hospitalization, unscheduled, including emergency department visits

Trial Locations

Locations (16)

CH d'Albi

πŸ‡«πŸ‡·

Albi, France

Carcassonne Hospital

πŸ‡«πŸ‡·

Carcassonne, France

Limoges university hospital

πŸ‡«πŸ‡·

Limoges, France

CH de Cahors

πŸ‡«πŸ‡·

Cahors, France

Perpignan Hospital

πŸ‡«πŸ‡·

Perpignan, France

CH Lavaur

πŸ‡«πŸ‡·

Lavaur, France

CH Lannemezan

πŸ‡«πŸ‡·

Lannemezan, France

Lyon University Hospital

πŸ‡«πŸ‡·

Lyon, France

CHI Castres Mazamet

πŸ‡«πŸ‡·

Castres, France

Toulouse University Hospital (CHU de Toulouse)

πŸ‡«πŸ‡·

Toulouse, France

CH Montauban

πŸ‡«πŸ‡·

Montauban, France

Narbonne Hospital

πŸ‡«πŸ‡·

Narbonne, France

CHI Val d'Ariège

πŸ‡«πŸ‡·

Saint Girons, France

University Hospital Toulouse - Neurology department

πŸ‡«πŸ‡·

Toulouse, France

CH de Bigorre

πŸ‡«πŸ‡·

Vic en Bigorre, France

HNO-Franche-sur-SoΓ’ne

πŸ‡«πŸ‡·

Villefranche-sur-SaΓ΄ne, France

Β© Copyright 2025. All Rights Reserved by MedPath